| [1] |
Yuen CM, Amanullah F, Dharmadhikari A , et al. Turning off the tap: stopping tuberculosis transmission through active case-finding and prompt effective treatment. Lancet, 2015,386(10010):2334-2343.
doi: 10.1016/S0140-6736(15)00322-0
URL
|
| [2] |
Gao L, Lu W, Bai L , et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicenter, prospective cohort study. Lancet Infect Dis, 2015,15(3):310-319.
doi: 10.1016/S1473-3099(14)71085-0
URL
|
| [3] |
Zhao Y, Xu S, Wang L , et al. National survey of drug-resistant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170.
doi: 10.1056/NEJMoa1108789
URL
|
| [4] |
Rodo MJ, Rozot V, Nemes E , et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog, 2019,15(3):e1007643.
doi: 10.1371/journal.ppat.1007643
URL
|
| [5] |
Manjaly Thomas ZR, Satti I, Marshall JL , et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Med, 2019,16(4):e1002790.
doi: 10.1371/journal.pmed.1002790
URL
|
| [6] |
Kashangura R, Jullien S, Garner P , et al. MVA85A vaccine to enhance BCG for preventing tuberculosis. Cochrane Database Syst Rev, 2019, 4:CD012915.
|
| [7] |
Joosten SA, Ottenhoff THM, Lewinsohn DM , et al. Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. Vaccine, 2019,37(23):3022-3030.
doi: 10.1016/j.vaccine.2019.04.050
URL
|
| [8] |
Kumarasamy N, Poongulali S, Beulah FE , et al. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase Ⅱ randomized controlled trial. Medicine (Baltimore), 2018,97(45):e13120.
doi: 10.1097/MD.0000000000013120
URL
|
| [9] |
Van Der Meeren O, Hatherill M, Nduba V , et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med, 2018,379(17):1621-1634.
doi: 10.1056/NEJMoa1803484
URL
|
| [10] |
Vekemans J, Gebreselassie N, Zignol M , et al. A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration. Lancet Infect Dis, 2019,19(2):123-125.
doi: 10.1016/S1473-3099(19)30003-9
URL
|
| [11] |
de Oliveira Viana J, Ishiki HM, Scotti MT , et al. Multi-target antitubercular drugs. Curr Top Med Chem, 2018,18(9):750-758.
doi: 10.2174/1568026618666180528124414
URL
|
| [12] |
Lee SFK, Laughon BE, McHugh TD , et al. New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med, 2019,25(3):271-280.
doi: 10.1097/MCP.0000000000000570
URL
|
| [13] |
Hatherill M, Chaisson RE, Denkinger CM , et al. Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies. PLoS Med, 2019,16(4):e1002795.
doi: 10.1371/journal.pmed.1002795
URL
|
| [14] |
Martinez L, Lo NC, Cords O , et al. Paediatric tuberculosis transmission outside the household: challenging historical para-digms to inform future public health strategies. Lancet Respir Med, 2019. pii:S2213- 2600(19) 30137-7. [Epub ahead of print].
|
| [15] |
杨健, 张天华, 鲜小萍 , 等. 2017—2018年陕西省涂阳肺结核患者临床分离株的耐药性检测结果分析. 中国防痨杂志, 2019,41(6):616-623.
|
| [16] |
孙照刚, 张洪静, 李自慧 , 等. 新一代微测序基因芯片的设计及其耐药性检测效果的初步研究. 中国防痨杂志, 2019,41(6):609-615.
|
| [17] |
赵皎洁, 陆宇 . 抗结核药物药代动力学/药效学的研究及进展. 中国防痨杂志, 2019,41(6):700-704.
|
)
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
